BTEC Seminar on Lentiviral Manufacturing by Rachel Legmann

Speaker: Rachel Legmann, Senior Director of Technology and Gene Therapy at Repligen

Talk Title: Powering the Future of LentiviralManufacturing: Continuous Perfusion for in vivo Cell and Gene Therapies

Abstract: The rapid expansion of in vivo gene and cell therapies is redefining lentiviral vector (LV) manufacturing requirements. Systemic delivery demands significantly higher vector quantities, consistent quality, and cost-effective scalability, which traditional batch-based HEK293 transient transfection platforms were not designed to deliver. This presentation highlights how continuous, scalable perfusion enables a transformative shift in LV manufacturing tailored for in vivo applications. We demonstrate a robust, scalable platform capable of supporting large-scale (up to 2,000 L) commercial manufacturing for in-vivo gene and cell therapies.

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher BTEC- Biomanufacturing Training & Education Center